Edwards Lifesciences revenue and financials
$86.48Change from previous close: −0.86%Absolute change: −$0.75
In the fiscal year ended December 2025, Edwards Lifesciences reported revenue of $6.07B (+11.55% year over year). Net income was $1.07B, a net margin of 17.7%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +11.55%
- 2025 vs 2024
- Net income growth
- −74.28%
- 2025 vs 2024
- Net margin
- 17.7%
- 2024: 76.7%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 652 | 43.8 | 451 | 574 | 290 | 280 | -128 | 372 | -53.5 | 137 | 412 | 33.6 |
| Depreciation and amortization | 42.7 | 40.9 | 42.7 | 39.2 | 38.1 | 36.6 | 42.7 | 39.6 | 38.5 | 36.7 | 36.9 | 36.1 |
| Capital expenditure | -66.9 | -64.9 | -97.4 | -57.5 | -49.3 | -56.0 | -49.8 | -85.4 | -65.3 | -88.3 | -55.3 | -47.9 |
| Investing cash flow | -193 | -92.8 | -198 | -428 | -172 | 85.3 | -577 | 125 | 63.1 | 14.1 | 89.0 | 70.2 |
| Financing cash flow | -0.3 | -451 | -11.4 | -740 | 52.7 | -258 | 28.6 | -96.6 | 61.7 | -413 | -143 | 52.1 |
| Share repurchases | -53.3 | -522 | -40.6 | -539 | -5.5 | -309 | -0.1 | -158 | -0.2 | -448 | -174 | -7.5 |
| Effect of exchange rates | 3.8 | 8.2 | 3.5 | -1.0 | -29.6 | -17.7 | 51.0 | 29.4 | 9.7 | -3.4 | 9.2 | 15.2 |
| Net change in cash | 462 | -492 | 245 | -595 | 141 | 90.0 | -625 | 429 | 81.0 | -266 | 366 | 171 |
| Free cash flow | 585 | -21.1 | 354 | 516 | 241 | 224 | -177 | 286 | -119 | 48.3 | 356 | -14.3 |
| Levered free cash flow | 433 | -106 | 437 | 469 | 103 | 162 | -237 | 282 | 65.0 | 71.8 | 257 | 113 |